Case Report
Year 2020,
Volume: 10 Issue: 1, 138 - 142, 16.03.2020
Abstract
Öz
Hepatoselüler karsinom en sık primer karaciğer
malignitesi olup küratif tek tedavi seçeneği karaciğer transplantasyonudur. Kronik viral hepatit B’ye bağlı
dekompanse karaciğer sirozu ve 5 cm.lik hepatoselüler karsinom odağı nedeniyle
canlı vericili karaciğer transplantasyonu uygulanmış olan 67 yaşında erkek
hastanın post-transplant 2. yılında tüm biyokimyasal verileri, abdominal ve
toraks BT’si normal olmasına rağmen sırt ağrısı nedeniyle çekilen dorsal MR’da
D7 seviyesinde 2.5 cm.lik nüks gelişmiştir. Radyoterapi ve sonrasında cerrahi
uygulanmıştır. Karaciğer
transplantasyonu sonrası nüksler sıklıkla ekstrahepatik alanlarda
gelişmektedir. Nadiren de olsa kemik ağrısı olanlarda akılda bulundurulmalıdır.
Erken tanı ile erken nüks tedavisi mümkün olmaktadır.
Keywords
References
- 1. Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg 2011; 34: 128-134.
- 2. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
- 3. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540.
- 4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
- 5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
- 6. Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007;25:299–302.
- 7. Miyagi S, Kawagishi N, Sekiguchi S, Akamatsu Y, Sato K, Takeda I, et al. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma. Transplant Proc 2012;44(3):797-801.
- 8. Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, Sa Cunha A, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?. Livert Transplant. 2017; 23 (4):440-447. doi:10.1002/lt.24742.
- 9. Günay Y, Güler N, Akyıldız M, Dayangaç M, Yaprak O, Yüzer Y, Tokat Y. Hepatosellüler karsinoma ve canlı vericili karaciğer nakli; kanser nüksü ve hasta sağkalımını etkileyen faktörler. Tek merkez deneyimi. Gaziantep Med J. 2013; 19 (3):173-179.
Year 2020,
Volume: 10 Issue: 1, 138 - 142, 16.03.2020
Abstract
References
- 1. Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg 2011; 34: 128-134.
- 2. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
- 3. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540.
- 4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
- 5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
- 6. Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007;25:299–302.
- 7. Miyagi S, Kawagishi N, Sekiguchi S, Akamatsu Y, Sato K, Takeda I, et al. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma. Transplant Proc 2012;44(3):797-801.
- 8. Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, Sa Cunha A, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?. Livert Transplant. 2017; 23 (4):440-447. doi:10.1002/lt.24742.
- 9. Günay Y, Güler N, Akyıldız M, Dayangaç M, Yaprak O, Yüzer Y, Tokat Y. Hepatosellüler karsinoma ve canlı vericili karaciğer nakli; kanser nüksü ve hasta sağkalımını etkileyen faktörler. Tek merkez deneyimi. Gaziantep Med J. 2013; 19 (3):173-179.
There are 9 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | March 16, 2020 |
| Submission Date | December 11, 2019 |
| Published in Issue | Year 2020 Volume: 10 Issue: 1 |
The published articles in SMJ are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.